Skip to main content
. 2021 Jun 21;23(9):1518–1524. doi: 10.1002/ejhf.2259

Figure 1.

EJHF-2259-FIG-0001-c

β‐blocker dosing categorized into patients not on therapy, and patients on 1–49%, 50–99%, and 100%+ of target dose by treatment assignment with enalapril (Ena) vs. sacubitril/valsartan (Sac/Val) at baseline, and 6‐ and 12‐month follow‐up. 100%+ reflects dosing that equals or exceeds target doses recommended in clinical practice guidelines.